Research progress of bone marrow-derived mesenchymal stem cells in blood diseases

( views:, downloads: )
Author:
WANG Yun(Department of Hematology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China)
TAO Rong(Department of Hematology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China)
LIANG Hui(Department of Hematology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China)
Journal Title:
JOURNAL OF LEUKEMIA & LYMPHOMA
Issue:
Volume 19, Issue 01, 2010
DOI:
10.3760/cma.j.issn.1009-9921.2010.01.024
Key Word:
Mesenchymal stem cells; Hematologic diseases

Abstract: Bone marrow mesenchymal stem cells (MSC) are the non-hematopoietic cellular component in the bone marrow that have multiple differentiation potency. MSC play a key role in the regulation of bone marrow hematopoietic niche and modulation of immune function through various mechanisms. They are currently recognized as a promising cell source in tissue engineering, a vehicle in gene therapy and a powerful tool in the management of graft-versus-host disease after allogeneic stem cell transplantation. In this review some momentous aspects regarding the current status and potential clinical applications of MSC in hematopoietic stem cell transplantation, aplastic anemia and multiple myeloma were summarized.

  • [1]Adams GB,Scadden DT.The hematopoietic stem cell in its place.Nat Immunol,2006,7:333-337.
  • [2]Dazzi F,Ramasamy R,Glennie S,et al.The role of mesenchymal stem cells in haemopoiesis.Blood Rev,2006,20:161-171.
  • [3]Haynesworth SE,Baber MA,Caplan AI.Cell surface antigens on human marrow-derived mesenchymal cells are detected by monoclonal antibodies.Bone,1992,13:69-80.
  • [4]Pittenger MF,Mackay AM,Beck SC,et al.Multilineage potential of adult human mesenchymal stem cells.Science,1999,284:143-147.
  • [5]Le Blanc K,Tammik C,Rosendahl K,et al.HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells.Exp Hematol,2003,31:890-896.
  • [6]Glennie S,Soeiro I,Dyson PJ,et al.Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells.Blood,2005,105:2821-2827.
  • [7]Maccario R,Podesta M,Moretta A,et al.Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD_4~+ T-cell subsets expressing a regulatory/suppressive phenotype.Haematologica,2005,90:516-525.
  • [8]Jiang XX,Zhang Y,Liu B,et al.Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells.Blood,2005,105:4120-4126.
  • [9]Aggarwal S,Pittenger MF.Human mesenchymal stem cells modulate allogeneic immune cell responses.Blood,2005,105:1815-1822.
  • [10]Corcione A,Benvenuto F,Ferretti E,et al.Human mesenchymal stem cells modulate B-cell functions.Blood,2006,107:367-372.
  • [11]Spaggiari GM,Capobianco A,Becchetti S,et al.Mesenchymal stem cell-natural killer cell interactions:evidence that activated NK cells are capable of killing MSCs,whereas MSCs can inhibit IL-2-induced NK-cell proliferation.Blood,2006,107:1484-1490.
  • [12]Sotiropoulou PA,Perez SA,Gritzapis AD,et al.Interactions between human mesenchymal stem cells and natural killer cells.Stem Cells,2006,24:74-85.
  • [13]Meuleman N,Tondreau T,Ahmad I,et al.Infusion of mesenchymal stromal cells can aid hematopoietic recovery following allogeneic hematopoietic stem cell myeloablative transplant:a pilot study.Stem Cells Dev,2009,18:1247-1252.
  • [14]Ball LM,Bernardo ME,Roelofs H,et al.Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation.Blood,2007,110:2764-2767.
  • [15]Guo M,Sun Z,Sun QY,et al.A modified haploidentical nonmyeloablative transplantation without T cell depletion for high-risk acute leukemia:successful engraftment and mild GVHD.Biol Blood Marrow Transplant,2009,15:930-937.
  • [16]Gonzalo-Daganzo R,Regidor C,Martin-Donaire T,et al.Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults.Cytotherapy,2009,11:278-288.
  • [17]Tian Y,Deng YB,Huang YJ,et al.Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.Immunol Invest,2008,37:29-42.
  • [18]Ringden O,Uzunel M,Rasmusson I,et al.Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease.Transplantation,2006,81:1390-1397.
  • [19]Le Blanc K,Frassoni F,Ball L,et al.Mesenchymal stem cells for treatment of steroid-resistant,severe,acute graft-versus-host disease:a phase II study.Lancet,2008,371:1579-1586.
  • [20]Prigozhina TB,Khitrin S,Elkin G,et al.Mesenchymal stromal cells lose their immunosuppressive potential after allotransplantation.Exp Hematol,2008,36:1370-1376.
  • [21]吴艳,于洁,张磊,等.再生障碍性贫血患儿骨髓间充质干细胞体外造血支持作用的研究.中国当代儿科杂志,2008.10:455-459.
  • [22]王海燕,丁天凌,谢毅,等.再牛障碍性贫血患者骨髓间充质十细胞成脂和成骨分化能力的变化.中华内科杂志.2009,48:39-43.
  • [23]Bacigalupo A,Valle M,Podesta M,et al.T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia.Exp Hematol,2005,33:819-827.
  • [24]赵秀娟,乔振华.再生障碍性贫血患者骨髓问充质干细胞的造血实验研究.中华内科杂志,2007.46:681-682.
  • [25]Le Blanc K,Samuelsson H,Gustafsson B,et al.Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells.Leukemia,2007,21:1733-1738.
  • [26]Fang B,Li N,Song Y,et al.Cotransplantation of haploidentical mesenchymal stem cells to enhance engraftment of hematopoietic stem cells and to reduce the risk of graft failure in two children with severe aplastic anemia.Pediatr Transplant,2009,13:499-502.
  • [27]Arnulf B,Lecourt S,Soulier J,et al.Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma.Leukemia,2007,21:158-163.
  • [28]Morvan F,Boulukos K,Clement-Lacroix P,et al.Deletion of a single allele of the Dkkl gene leads to an increase in bone formation and bone mass.J Bone Miner Res,2006,21:934-945.
  • [29]Gunn WG,Conley A,Deininger L,et al.A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6:a potential role in the development of lytic bone disease and tumor progression in multiple myeloma.Stem Cells,2006,24:986-991.
  • [30]Hideshima T,Mitsiades C,Tonon G,et al.Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.Nat Rev Cancer,2007,7:585-598.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn